EP4615431A1 — Combination therapies for the treatment of cancer
Assigned to AstraZeneca AB · Expires 2025-09-17 · 1y expired
What this patent protects
The present specification relates to the use of an AKT inhibitor, a PI3K-α inhibitor or an mTOR (such as mTORC1) inhibitor in combination with a KDM5C inhibitor to treat cancer, for example breast cancer. Also described is a pharmaceutical composition comprising a compound, a KDM…
USPTO Abstract
The present specification relates to the use of an AKT inhibitor, a PI3K-α inhibitor or an mTOR (such as mTORC1) inhibitor in combination with a KDM5C inhibitor to treat cancer, for example breast cancer. Also described is a pharmaceutical composition comprising a compound, a KDM5C inhibitor, and a pharmaceutically acceptable excipient, where the compound is an AKT inhibitor, a PI3K-α inhibitor or an mTOR inhibitor
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.